Efficacy and safety of the first and repeated intradetrusor injections of abobotulinum toxin A 750 U for treating neurological detrusor overactivity

Abstract

The results of the present study are in favor of a long-term safety and efficacy of abobotulinum toxin A 750 U for NDO.

The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis

“…In a retrospective study with a mixed group of neurological patients with refractory LUT dysfunction using intradetrusor injections of 750 IU abobotulinumtoxinA, 64% of patients reported significantly improved continence rates after 6 weeks and a reduction in mean maximum detrusor pressures comparable to after onabotulinumtoxinA use. The study confirmed long-time safety and efficacy of abobotulinumtoxinA 750 IU over a mean follow-up of 28 months [ 71 ••].…”

Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia

“…According to their study, after treatment 19 patients had a significant decrease in mean maximum detrusor voiding pressure at 36 weeks follow-up. Furthermore, over the past 15 years there has been rapid progress in research into the clinical and urodynamic benefits of BTX-A for NDO secondary to SCI (21). Although the follow-up period was relatively short, our trial also reported an mean reduction of 28.78 cm H 2 O in maximum detrusor pressure (P detmaxDO-DESD ) and a mean increase of 54.56 ml in V DO-DESD .…”

Is repeat Botulinum Toxin A injection valuable for neurogenic detrusor overactivity—A systematic review and meta‐analysis

“…[11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] The level of evidence of the included studies ranged from 3 to 4. Ten studies were retrospective case series, [12][13][14][15][16][17][18][19]22,27 seven studies were prospective cohort studies 11,20,21,23,24,26,28 and the remaining article was a mixed study comprising both retrospective and prospective components. 25 Thirteen studies used Botox, 12,15,[17][18][19][20][21][23][24][25][26][27][28] four studies used Dysport, …”

“…Ten studies were retrospective case series, [12][13][14][15][16][17][18][19]22,27 seven studies were prospective cohort studies 11,20,21,23,24,26,28 and the remaining article was a mixed study comprising both retrospective and prospective components. 25 Thirteen studies used Botox, 12,15,[17][18][19][20][21][23][24][25][26][27][28] four studies used Dysport, 13,14,16,22 and one study used both Botox and Dysport. 11 Botox was administered at doses of 200 or 300 U, and Dysport was administered at doses ranging from 500 to 1000 U.…”

“…13 The remaining studies did not include information regarding anticholinergic use during treatment. 12,18,21,22,25,26,28 The number of patients receiving repeat BTX-A injections varies throughout the literature, as it ranges from 20 to 388. The number of patients who received repeat injections and the percentage of patients who continued receiving injections after each injection are shown in Table 2.…”